Prelude Therapeutics (PRLD) has just posted its FY 2025 numbers, with Q4 revenue of US$5.6 million, a basic EPS loss of US$0.21, and net income excluding extra items showing a loss of US$16.5 million. Over recent quarters the company has seen revenue move from US$4 million in Q4 2024 to US$6.5 million in Q3 2025 before landing at US$5.6 million in Q4 2025, while basic EPS has ranged from a loss of US$0.38 in Q4 2024 to a peak quarterly loss of US$0.42 in early 2025 and then US$0.21 in the latest quarter. For investors, the focus now is on how these revenue contributions compare with ongoing losses and what that might indicate about progress toward healthier margins.

See our full analysis for Prelude Therapeutics.

With the headline numbers on the table, the next step is to see how this earnings report aligns with the most widely discussed views on Prelude's growth potential, risk profile, and longer term margin trajectory.

Losses Still Heavy On A Full Year View

• On a trailing 12 month basis, Prelude reported US$12.14 million of revenue and a net loss of US$99.50 million, so the losses are still much larger than the revenue being generated.
• Bulls highlight that analysts in this dataset expect earnings to grow around 59.14% per year and see a path to profitability within three years, yet that enthusiasm sits against a recent history where losses have grown about 7.3% per year over five years and the latest trailing loss is close to US$100 million.
  • Supporters point to the JAK2V617F and KAT6A programs, plus the Incyte and AbCellera relationships, as potential drivers of the forecast earnings improvement, even though current reported numbers still show sizeable net losses.
  • The bullish view also leans on long term scenarios where margins could eventually turn positive. At the same time, the present trailing EPS of about US$1.29 loss per share underlines how much progress is needed for those forecasts to play out in the financial statements.

If you are trying to square these large current losses with optimistic earnings forecasts, it is worth seeing how bullish investors join the dots between the pipeline, margins and long term EPS projections. 🐂 Prelude Therapeutics Bull Case

High Revenue Multiple Despite Unprofitability

• Prelude is trading at a P/S of 24.4x, compared with 26.8x for the peer set and 12.3x for the broader US biotechs industry, even though the company remains unprofitable on a trailing basis.
• Skeptics argue this higher than industry multiple and the history of widening losses could limit upside even if growth materialises, since the stock is already valued well above many biotech names that also have no current profits.
  • The bearish narrative points to five year loss growth of about 7.3% annually and recent trailing net losses above US$99 million as evidence that the business has not yet converted its science into financially self funding operations.
  • Critics also flag recent share price volatility as a key risk. They suggest that if trial timelines slip or data is less compelling than hoped, a rich P/S multiple and unstable share price could amplify the impact of any disappointment on investor returns.

Skeptical investors often focus on how much is already priced in, and here the mix of a rich sales multiple, sizeable losses and a jumpy share price makes that question especially pointed. 🐻 Prelude Therapeutics Bear Case

DCF Gap Versus US$3.60 Share Price

• The DCF fair value in this dataset is US$24.64 per share, compared with a current share price of US$3.60 and an analyst consensus price target of US$4.00, so the DCF figure sits well above where the market and analysts are currently pricing Prelude.
• Supporters of the bullish view see this large DCF gap, combined with forecast revenue growth of 28.1% per year, as a sign that the market may be focusing more on today’s losses than the potential earnings power of the pipeline.
  • At the same time, the consensus target of US$4.00 is much closer to the current price than to the DCF fair value. This shows that even analysts who model strong growth are more conservative than the DCF output in this dataset.
  • For you as an investor, the tension between a very high modelled fair value, a modest analyst target and a company that is still loss making highlights why it is important to check your own assumptions about future revenue, margins and funding needs against the raw numbers.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Prelude Therapeutics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With bulls and bears both making strong cases, it helps to look at the full picture yourself and decide where you stand. Our data highlights both risks that investors are watching and rewards they are hopeful about, so it is worth reviewing the 2 key rewards and 1 important warning sign before you settle on your own view.

Explore Alternatives

Prelude is still posting sizeable losses close to US$100 million on modest revenue of US$12.14 million, with a relatively rich P/S multiple despite ongoing unprofitability.

If that mix of heavy losses, volatile sentiment and rich pricing feels uncomfortable, you may want to focus on companies screened for more resilient profiles through 68 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.